These statins have been linked to an increase in chromosomal abnormalities in RB-deficient tumor cells, hinting at their potential application for the treatment of RB-deficient tumors.134 Ongoing clinical trials are currently examining the efficacy of simvastatin against various cancers, including breast (NCT00807950, NCT05550415), gastric (NCT01099085, NCT03086291), colorectal (NCT01238094), and bladder (NCT02360618) cancer. Here, RB1 is linked to neoplasm.